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Abstract
Loss of Parkin, encoded by PARK2 gene, is a major cause of autosomal recessive Parkinson’s disease. In Drosophila and
mammalian cell models Parkin has been shown in to play a role in various processes essential to maintenance of
mitochondrial quality, including mitochondrial dynamics, biogenesis and degradation. However, the relevance of altered
mitochondrial quality control mechanisms to neuronal survival in vivo is still under debate. We addressed this issue in the
brain of PARK22/2 mice using an integrated mitochondrial evaluation, including analysis of respiration by polarography or
by fluorescence, respiratory complexes activity by spectrophotometric assays, mitochondrial membrane potential by
rhodamine 123 fluorescence, mitochondrial DNA content by real time PCR, and oxidative stress by total glutathione
measurement, proteasome activity, SOD2 expression and proteins oxidative damage. Respiration rates were lowered in
PARK2
2/2 brain with high resolution but not standard respirometry. This defect was specific to the striatum, where it was
prominent in neurons but less severe in astrocytes. It was present in primary embryonic cells and did not worsen in vivo
from 9 to 24 months of age. It was not associated with any respiratory complex defect, including complex I. Mitochondrial
inner membrane potential in PARK22/2 mice was similar to that of wild-type mice but showed increased sensitivity to
uncoupling with ageing in striatum. The presence of oxidative stress was suggested in the striatum by increased
mitochondrial glutathione content and oxidative adducts but normal proteasome activity showed efficient compensation.
SOD2 expression was increased only in the striatum of PARK22/2 mice at 24 months of age. Altogether our results show a
tissue-specific mitochondrial defect, present early in life of PARK22/2 mice, mildly affecting respiration, without prominent
impact on mitochondrial membrane potential, whose underlying mechanisms remain to be elucidated, as complex I defect
and prominent oxidative damage were ruled out.
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Introduction
Mitochondrial dysfunction has long been thought to play a key
role in Parkinson’s disease (PD) pathogenesis. Parkinsonian
syndromes are induced in humans and animals by complex I
inhibitors, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) or rotenone, and complex I activity has been reported to
be reduced in different tissues from patients, suggesting that this
defect may contribute to neuronal degeneration in PD [1,2].
Mitochondrial dysfunction has also been suggested to contribute to
oxidative damage and apoptosis in idiopathic PD brains [3].
Identification of genetic causes of familial PD reinforced a central
role for mitochondria in PD pathogenesis [4,5]. Indeed most
autosomal recessive forms were found to be caused by the
alteration of a gene encoding a protein localized to mitochondria,
either in particular contexts, as in the case of Parkin [6] and DJ-1
[7], or constitutively for PINK1 [8]. Furthermore, studies in
various models and from many independent laboratories have
provided evidence for interaction between the PARK2 and PINK1
genes and their protein products in a common pathway centered
on maintenance of mitochondrial quality [9]. In cell models Parkin
and PINK1 regulate the elimination of dysfunctional mitochon-
dria through mitophagy [10–15]. Parkin and PINK1 have also
been involved in mitochondrial fission and fusion [16–18],
mitochondrial transport [19,20], and mitochondrial biogenesis
[21,22], processes that are also relevant to mitochondrial quality.
Consistent with these findings, PARK2 or PINK1 inactivation have
been reproducibly linked with partial mitochondrial depolariza-
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tion [23–25], reduced respiration rates [22,24,26,27] and/or
reduction in the enzymatic activity of complex I of the
mitochondrial electron transport chain [24–30].
However, the in vivo relevance of the PINK1/Parkin-dependent
mitochondrial quality control mechanisms for neuronal cells has
recently been questioned [31,32]. In addition, PINK1- or Parkin-
deficient mouse models have less consistently shown mitochondrial
defects than cellular models, possibly due to differences in the ages
and tissues examined and in the methodologies used [26,33–37].
Several groups, including ours, have generated Parkin-deficient
mice and shown that, in general, they do not present with overt
signs of neuronal degeneration in the nigrostriatal pathway, even
at high ages [38–42]. In some cases, including our model,
moderate alterations in dopamine handling evocative of presymp-
tomatic changes have been reported in the striatum, such as
increased extracellular dopamine content, enhanced dopamine
metabolism via monoamine oxidase and decreased motor
activation following amphetamine-induced dopamine-release
[38,39]. Therefore, despite the lack of manifest parkinsonian
phenotype, these mice may be valuable for investigation of early
disease-related modifications and compensatory mechanisms. To
clarify discrepancies in the literature regarding the role of
mitochondrial dysfunction in these models [35,37], we have
investigated mitochondrial functions, including respiration, respi-
ratory complexes activity and inner membrane potential, in mice
carrying a germline homozygous deletion of PARK2 exon 3 [39].
To address potential technical biases underlying the literature
discrepancies, we analyzed respiration in different mitochondrial
and tissue preparations, including crude mitochondrial pellets
from striatum and cortex, purified mitochondria from whole
brain, and post-nuclear supernatants from midbrain and striatum;
we also examined primary embryonic neurons and astrocytes from
striatum or cortex. We provide evidence for tissue- and cell-type-
specific reduction of mitochondrial respiratory capacity in
PARK2
2/2 mice. These defects were observed in the absence of
overt oxidative damage, decreased mitochondrial membrane
potential or defective enzymatic activities of the respiratory chain
complexes, thus leaving open their underlying mechanisms.
Materials and Methods
Ethics statement
All experiments were approved by the ‘‘Comite´ d’Ethique pour
l’expe´rimentation animale Charles Darwin’’ (Ce5/2009/052).
Generation of experimental groups
PARK2
2/2 mice were generated and brought into the C56Bl/6j
genetic background as previously described [39,42]. Experimental
groups of age-matched littermate PARK22/2 and wild type mice
were generated by intercross of heterozygous PARK22/+ mice.
Genotypes were determined by PCR amplification [42]. After
weaning, male and female mice were separated and maintained at
a maximum of five littermates per cage, with food and water ad
libitum, and at constant temperature (20uC+/22uC) with a 08:00–
18:00 light cycle. The experiments were performed on female mice
(n = 42 per genotype) as follows, with n corresponding to the
number of animals per genotype, 24-month-old mice were used
for respiration analyses on crude mitochondrial pellets (n = 8),
purified mitochondrial pellets (n = 2) or post-nuclear supernatants
(n = 8), and oxidative stress evaluation with glutathione and
proteasome studies (n = 5), 9-month-old mice for respiration
analyses on post-nuclear supernatants (n = 7), 12-month-old mice
for respiratory chain complexes assays (n = 7), and oxidative stress
evaluation with glutathione and proteasome studies (n = 5). For all
applications, mice were killed by decapitation, without prior
anesthesia.
Tissue preparation
After mice decapitation, liver and brain were rapidly removed
and the regions of interest dissected on ice. All samples were
manually homogenized using a Dounce homogenizer with a
Teflon pestle. The scheme depicting the different tissue prepara-
tions and their use is shown in Figure S1.
Crude mitochondrial pellets from the striatum or cortex were
obtained by homogenization in 9 volumes of Buffer A (50 mM
Tris HCl, 5 mM Glucose, 1 mM Pyruvate, 1 mM EGTA,
150 mM KCl, pH 7.5). Centrifugation for 5 min at 1000 g gave
post-nuclear supernatant. The nuclei and tissue particles in the
pellet was subjected to a second identical cycle of homogenization
and centrifugation. The two post-nuclear supernatants were
collected and centrifuged for 10 min at 10,000 g to obtain the
crude mitochondrial pellet that was diluted in 120 and 240 ml of
Buffer A for striatal and cortical mitochondria respectively. These
suspensions were used for respiration and protein assay. Between 5
and 10 mg mitochondrial proteins were used per run of respiration.
Purified brain mitochondria were obtained by homogenization
of a whole brain in 1 mL Mannitol-Sucrose (MS) isolation
medium (225 mM mannitol, 75 mM sucrose, 1 mM EGTA,
5 mM HEPES, pH 7.4) containing 0.1 mg/mL fatty acid-free
bovine serum albumin (FAF-BSA) [43]. The homogenate volume
was brought to 1.5 ml. The supernatant of a first centrifugation
during 6 min at 500 g was centrifuged during 10 min at 14 000 g
to obtain the crude mitochondrial pellet that was diluted in 200 ml
of 12% Percoll solution in MS buffer, layered on top of a
discontinuous Percoll gradient (200 ml of 12% Percoll on top of
1 mL of 24% Percoll in MS buffer), and centrifuged during
18 min at 17 000 g. The resulting mitochondrial pellet was
washed twice with MS buffer with centrifugation during 7 min
at 17 000 g the first time and during 5 min at 14 000 g the second
time. The last purified mitochondrial pellet was diluted in 100 ml
MS buffer and used for respiration (5 mg of mitochondrial proteins
per run) and protein assays.
Liver, ventral midbrain and striatal post-nuclear supernatants
were obtained by homogenization in 9 volumes of 300 mM
sucrose, 1 mM EGTA, 5 mM Tris HCl pH 7.4, followed by
centrifugation during 10 minutes at 1000 g. The post-nuclear
supernatants were directly used for respiration and protein assays,
as well as for the analysis of inner mitochondrial membrane
potential. Each run of respiration assay used 300 mg of protein of
post-nuclear supernatant from midbrain or striatum and 1 mg
from liver.
Primary striatal or cortical neurons were prepared at embryonic
day 16 by a method adapted from Friedman et al [44]. In
summary, following centrifugation through a BSA cushion,
primary neurons were seeded onto poly-ornithine and laminin
coated Seahorse 24-well plates (175,000 cells/well for striatal
neurons and 140,000 cells/well for cortical neurons) and cultured
for 7 days at 37uC, 5% CO2 in Neurobasal medium supplemented
with 2% B27, 1 mM sodium pyruvate and 1 mM glutamax.
Astrocytes were isolated from striatum or cortex of newborn
mice as previously described [45] and cultured in poly L-lysine
coated tissue culture flasks (75 cm2) for 7 days. Astrocytes were
then trypsinized, plated in Seahorse 24-well plates (40,000 cells/
well) and cultured for another 4 days at 37uC, 5% CO2 in
Dulbecco’s modified Eagle’s medium F12 supplemented with 10%
fetal bovine serum and1% penicillin streptomycin.
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Respiration assays
For mitochondrial preparations or post-nuclear supernatants,
the rate of oxygen consumption was measured in a Clark-type
electrode. Mitochondrial pellets were analyzed by classical
respirometry using Hansatech electrode (Cambridge, UK). The
respiration medium was 100 mM KMES, 5 mM KH2PO4, 1 mM
EGTA, 3 mM EDTA, 0.4% w/v FAF-BSA, pH 7.4 for crude
mitochondrial pellets. It was 125 mM KCl, 1 mM MgCl2, 2 mM
KH2PO4, 20 mM HEPES, 200 mM EGTA, 0.2% w/v FAF-BSA,
pH 7.4 for purified mitochondria. Post-nuclear supernatants were
analyzed by high resolution respirometry with an Oroboros
apparatus (Innsbruck, Austria) using 100 mM KCl, 40 mM
sucrose, 10 mM TES, 5 mM MgCl2, 1 mM EGTA, 0.4% w/v
FAF-BSA, pH=7.2 as respiration medium.
Common recorded parameters were the respiration rate in the
presence of 10 mM glutamate, 5 mM malate and 1 mM ADP, in
the presence of 1 mg/mL oligomycin, a complex V inhibitor, and
in the presence of 1 mM KCN (=non-respiratory oxygen
consumption). These parameters allowed the calculation of state
3 respiration= respiration in the presence of substrates+ADP -
non-respiratory oxygen consumption, state 4 respiration= respira-
tion in the presence of oligomycin - non-respiratory oxygen
consumption, and respiratory control ratio = state 3/state 4,
evaluating the efficiency of the oxidative phosphorylation
coupling. Two additional parameters were recorded with
Oroboros electrode: basal respiration (in the presence of substrates
before ADP addition) and maximal respiration rate (maximal rate
obtained by progressive additions of 1.25 mM carbonyl cyanide m-
chlorophenyl hydrazone (cccp), a protonophore dissipating the
inner membrane potential, performed after the step with addition
of oligomycin). These additional parameters were used to calculate
the respiratory reserve =maximal respiration - basal respiration.
For primary neurons and astrocytes, respiration was analyzed in
a XF24 extracellular flux analyzer (Seahorse Bioscience) in the
presence of 25 mM glucose [46]. Subsequent steps included
complex V inhibition by oligomycin, inner membrane potential
dissipation by tri-fluorocarbonylcyanide phenylhydrazone (fccp),
and respiration inhibition by rotenone and antimycin, complex I
and complex III inhibitors respectively. For each cell type,
preliminary experiments determined the concentration of these
agents to optimally inhibit or stimulate respiration without
inducing toxicity (as mentioned in the figure legend). To measure
the relative cell density and viability in each well after respiration
measurements, cells were incubated during 20 minutes with 2 mg/
ml calcein-AM, a cell-permeant fluorogenic esterase substrate
whose fluorescence emission was measured at 532 nm, with
excitation set at 650 nm. For astrocytes, calcein global fluores-
cence was not proportional to cell number seeded, so the non-
mitochondrial OCR, which measures non mitochondrial oxidase
activity, was used to control for cell density equivalence. Cells from
wild type and PARK22/2 mice were seeded in different wells of the
same plate and only experiments with similar cell densities were
used for analysis. The recorded parameters were initial respiration,
state 4 respiration rate (respiration under oligomycin inhibition
minus non-respiratory oxygen consumption under rotenone and
antimycin) and maximal respiratory rate (respiration under fccp
minus non-respiratory oxygen consumption). The initial respira-
tion rate slightly differs from the basal respiration recorded with
mitochondrial pellets or post-nuclear supernatants because ADP
level cannot be controlled in intact cells. The difference between
maximal and initial respiration was thus named spare respiratory
capacity instead of respiratory reserve. Coupling efficiency was
evaluated by the ratio between initial respiration rate and
respiration under oligomycin (both after subtraction of the non-
respiratory oxygen consumption).
Mitochondrial activities
The maximal velocity of respiratory complexes and citrate
synthase activities was evaluated using standardized spectropho-
tometric assays used in the diagnosis of human mitochondrial
diseases [47] while complex V activity was assayed using the ATP
hydrolysis assay [48].
Determination of the mitochondrial transmembrane
potential
The mitochondrial membrane potential was evaluated in post-
nuclear supernatants using the fluorescent probe rhodamine 123,
which accumulates in the mitochondrial compartment according
to the Nernst law [49]. Incubation was performed at room
temperature with 2 to 5 mg protein of post-nuclear supernatants/
mL of respiration medium with 250 nM rhodamine 123, and in
diverse bioenergetic conditions: condition A= substrates (10 mM
glutamate+5 mM malate), condition B=A+1 mM ADP, condi-
tion C=B+1 mM oligomycin, condition D=C+1 mM cccp,
condition E=C+2 mM cccp, condition F=C+4 mM cccp, condi-
tion G=C+8 mM cccp, condition H=C+10 mM cccp and 1 mM
KCN. Reading was performed with an Accuri flow cytometer.
Results were expressed in mV as calculated by Nernst equation
after normalization of the fluorescence to the size of the objects as
measured by their forward scatter, taking into account the
proportion of mitochondrial objects (% of energizable objects
upon maximal energization), evaluating the mitochondrial volume
in the optic chamber of Accuri flow cytometer (estimated for brain
at 3% of the volume analyzed), and using condition H for
evaluation of the zero fluorescence.
Quantification of mitochondrial DNA
Quantification of mitochondrial DNA was performed in
striatum by quantitative real time PCR using as standard a
plasmid with the murine mitochondrial DNA-encoded MT-CO2
gene as an insert [50]. Results were expressed as copy number of
mitochondrial DNA/10 pg of total DNA, which roughly represent
a normal diploid genome.
Determination of cytosolic and mitochondrial
glutathione levels
Total glutathione levels were determined using 20 mg proteins
of crude mitochondrial pellet or cytosol from striatum and
midbrain with a modified version of the recycling enzymatic
assay based on the reduction of each GSSG molecule to give two
GSH molecules [51]. Standard curves were obtained with various
concentrations of GSSG and the values were thus expressed as
GSSG equivalent. Total glutathione content therefore equals 0.5
GSH+GSSG and is expressed in nmoles of glutathione/mg of
protein.
20S proteasome peptidase activity
The chymotrypsin-like activity of the proteasome was assayed in
cytosol from striatum and midbrain with the fluorogenic peptide
succinyl-Leu-Leu-Val-Tyr-amidomethylcoumarin (LLVY-AMC)
as substrate. 20 mg cytosolic proteins were incubated with
12.5 mM substrate in 25 mM Tris, pH 7.5 in a final volume of
200 ml [52]. Enzymatic kinetics was monitored in a temperature-
controlled microplate fluorimetric reader (Fluostar Galaxy; BMG,
Stuttgart, Germany). Excitation/emission wavelengths were
350 nm/440 nm.
Respiration Defect in Parkin2/2 Mice
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Western blot analyses
30 mg of proteins of crude mitochondrial pellets from striatum
or midbrain were solubilized overnight at room temperature in
sample buffer at a SDS/protein ratio = 30. Proteins were
separated by electrophoresis in 4–20% pre-cast gradient gels
(Biorad, Hertfordshire, UK) and transferred on nitrocellulose
membrane (Protran Whatman, Dassel, Germany). Antibodies
were rabbit polyclonal anti-SOD2 from Sigma and anti-nitrotyr-
osine from Molecular Probes, mouse monoclonal anti-VDAC
from Mitoscience and rabbit anti-4-hydroxynonenal (HNE)
produced in the team [52]; they were visualized using peroxi-
dase-conjugated secondary antibodies from Jackson ImmunoR-
esearch (Newmarket, UK).
Statistical methods
Statistics were performed with SigmaPlot 12.5 software. Non
parametric tests were used unless the data were shown to have a
normal distribution allowing the use of parametric tests. The
numbers given indicate independent measurements. Animals were
not pooled but always individually evaluated. Mean comparisons
were performed with Mann and Whitney test or unpaired Student
t test while paired comparisons were done by the Wilcoxon signed-
rank test or paired Student t test. Multiple comparison with the
Holm-Sidak test was used after verification of equal variance to
address the relative influence of age, genotype and their
interaction.
Results
High resolution respirometry and cell-type specific
analysis detect a respiration defect in PARK22/2 mice
Reductions in uncoupled respiratory rates have previously been
observed in the striatum or the substantia nigra of PARK22/2 mice
by two independent groups, with however partial inconsistency
with respect to the associated state 3 and state 4 respiration rates
[35,37]. Both reports relied on the analysis with standard
oxygraphy of relatively crude mitochondrial pellets obtained by
two successive centrifugation steps. Under these conditions, the
observed respiratory control ratios (state 3/state 4 respiration)
were low (below 3.5), reflecting relatively poor coupling of the
electron transport chain with ATP synthesis [35,37].
We performed similar experiments in aged mice considering
that they were more likely to express a defect because of the lack of
neurodegenerative phenotype in PARK22/2 mice [35,39,41] and
the relationship of PD with ageing. Crude mitochondrial pellets
from striatum and cortex were prepared from the brain of 24-
month-old mice (Figure S1). State 3 and state 4 respiration as well
as the respiratory control ratio were similar in PARK22/2 and wild
type mice (Figure 1A, B, C). As in the previous studies, the
respiratory control ratios were relatively low (Figure S2).
Considering that mild respiration defects might not be
detectable in crude mitochondrial pellets we next prepared whole
brain purified mitochondria from 24-month-old mice and found
similar state 3 and state 4 respiration as well as respiratory control
in PARK22/2 and wild-type mice (Figure 1D). Although
mitochondrial enrichment of the preparation was shown by the
higher specific respiratory rates as compared to those of crude
mitochondrial pellets, the respiratory control ratio of these purified
mitochondria was only slightly increased (Figure S2). Considering
the need to use whole brain instead of specific brain region, the
improvement of respiratory control ratio did not appear sufficient
to pursue that procedure in a higher number of animals.
Furthermore we reasoned that altered mitochondria were likely
to be eliminated during mitochondrial purification. That proce-
dure might thus be inappropriate when addressing mitochondrial
quality control as is the case in the absence of Parkin. Very low
respiration rates such as those observed without mitochondrial
enrichment can only be analyzed with high resolution respirom-
etry using Oroboros technology. We therefore optimized this
technique for the analysis of post-nuclear supernatants. The
relative rapidity of this tissue preparation allowed the parallel
study of striatum, midbrain and liver from each mouse. With this
method the respiratory control ratios were above 10 in midbrain
and striatum, indicating excellent mitochondrial preservation.
These ratios were similar between PARK22/2 and wild type mice
(Figure S2). An example of curve obtained with 300 mg striatum
post-nuclear supernatant is shown in Figure 2A. 24-month-old
PARK2
2/2 mice showed significant decreased respiratory reserve
in striatum when compared to wild type mice (p = 0.028 using
Mann and Whitney test). The concomitant decrease of state 3
respiration in striatum just failed to reach significance (p= 0.06
Figure 1. Respiration was similar in brain mitochondrial
preparations from 24-month-old PARK22/2 and wild type mice
examined with standard oxygraphy. (A) Representative experi-
ment with a crude mitochondrial pellet from striatum. Blue curve = oxy-
gen (O2) concentration expressed as nmol/mL; red curve = rate of
oxygen consumption expressed as nmoles O2/mL and min; ADP= addi-
tion of 400 mM ADP; OM=addition of 1 mg/mL oligomycin, a complex V
inhibitor; KCN = addition of 1 mM KCN (non-respiratory oxygen
consumption); (B, C, D) Bars showing state 3 respiration (respiration
in the presence of substrates +ADP – non-respiratory oxygen
consumption) and state 4 respiration (respiration in the presence of
oligomycin – non-respiratory oxygen consumption) on complex I
substrates (glutamate+malate); black bars = PARK22/2, white bars =wild
type; data are expressed as nmoles O2/mL and mg proteins and are
shown as means 6 SD; two animals, one per genotype, were analyzed
the same day; the numbers between brackets indicate the number of
individual animals of each genotype; (B) results from crude mitochon-
drial pellets from striatum (n= 6), (C) crude mitochondrial pellets from
cortex (n = 7) and (D) purified mitochondria from whole brain (n = 2).
doi:10.1371/journal.pone.0099898.g001
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with Mann and Whitney test) (Figure 2B). State 4 respiration was
not affected. The decreased state 3 respiration and respiratory
reserve in midbrain did not reach significance (Figure 2C) and
liver respiration was similar in both genotypes (Figure 2D).
Using the same approach we then studied younger mice at 9
months of age to address the presence of the respiratory defect
earlier in life. PARK22/2 mice presented with a decrease in state 3
respiration rate and respiratory reserve in midbrain and striatum
that was similar to the pattern observed in aged mice (Figure 2B).
As previously observed in aged mice, the decrease was only
significant in the striatum (p= 0.05 for state 3 respiration with
Mann and Whitney test).
Liver showed a significant age-associated decrease in respiratory
reserve capacity in both genotypes (Figure 2D). In contrast the
respiratory capacity in striatum and midbrain post-nuclear
supernatants was not modified by age.
Even precisely limited brain regions contain distinct cell
populations, which essentially are astrocytes and neurons. These
cells present with strikingly different energetic metabolism and
thus may develop different responses to the absence of Parkin [53].
Using Seahorse technology to evaluate the respiration of cultured
cells in multi-wells plates, we addressed this question by comparing
PARK2
2/2 and wild type pure primary embryonic neurons or
neonatal astrocytes from striatum or cortex (Figure 3). In striatal
neurons, the maximal respiration rate and spare respiratory
capacity were significantly reduced in the absence of Parkin. In
contrast they were similar in PARK22/2 and wild type cortical
neurons. Astrocytes strikingly differed from neurons with respect
to their uncoupled maximal respiration, which was equal or often
lower than their initial respiration. As a result, their spare
respiratory capacity appeared null or negative. This observation
contrasted with previously reported maximal respiration rates in
astrocytes that were at least two-fold higher than basal respiration
using Seahorse protocols without the step of oligomycin inhibition
[54,55]. We thus considered that our protocol wasnot suitable for
reliable evaluation of maximal respiration and only analyzed initial
respiration of astrocytes, which appeared mildly reduced in
PARK2
2/2 striatum and normal in cortex.
At the end of these diverse analyses of respiration it could be
concluded that the absence of parkin was associated with a mild
but significant striatal respiratory defect that did not appear to
worsen with age and was even detectable in embryonic neurons.
Figure 2. High resolution respirometry reveals a respiration defect in PARK22/2 mice. (A) Representative experiment with striatal post-
nuclear supernatant. Blue curve = oxygen concentration (O2) expressed as nmol/mL; red curve = rate of oxygen consumption expressed as nmoles
O2/mL and min; successive additions: ADP=1 mM ADP in the medium with 10 mM glutamate+5 mM malate; OM=1 mg/mL oligomycin,
cccp= successive additions of 1.25 mM (up to the maximal respiration rate independent from ATP synthase capacity); KCN= 1 mM KCN (non-
respiratory oxygen consumption); (B, C, D) Bars showing state 3 respiration, state 4 respiration and respiratory reserve on complex I substrates
(glutamate+malate) in post-nuclear supernatants from (B) striatum, (C) midbrain and (D) liver of 24- and 9-month-old PARK22/2 (black bars) and wild
type mice (white bars); all data are expressed as nmoles O2/mL and mg proteins and shown as means 6 SD; two animals, one per genotype, were
analyzed the same day; the data were obtained from 6 to 8 individual animals of each genotype. * p,0.05 using Mann and Whitney test. In liver, state
3 respiration rate and respiratory reserve significantly decreased with age in both wild type mice (p = 0.011 and ,0.001 when comparing state 3
respiration and respiratory reserve respectively between 9 and 24 months of age using Mann and Whitney test) and in PARK22/2 mice (p = 0.019 and
,0.001 when comparing state 3 respiration and respiratory reserve respectively between 9 and 24 months of age using Mann and Whitney test).
doi:10.1371/journal.pone.0099898.g002
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Mitochondrial inner membrane potential of PARK22/2
mice was normal but showed greater sensitivity to
uncoupling with ageing in the striatum
Low inner membrane potential (Dym) is one of the expected
consequences of a respiration defect. Furthermore it has been
proposed to be an important signal for Parkin translocation to
mitochondria and mitophagy [56]. To determine whether the
absence of Parkin translates in vivo into the presence of depolarized
mitochondria, we analyzed the Dym in midbrain, striatum and
liver of PARK22/2 and wild type mice, at 9 and 24 months of age
(Figure 4). The reliability of the method was demonstrated in the
three tissues by the significant decrease in Dym upon ADP
stimulation (condition B versus A, p,0.001 with Mann and
Whitney test), its increase upon inhibition of the ATP synthase
activity by oligomycin (condition C versus B, p,0.001), and
decrease with addition of uncoupler above 1 mM (condition C
versus E, F or G, p,0.001). The mean Dym did not significantly
differ between PARK22/2 and wild type mice in any of the
Figure 3. Maximal respiration is reduced in striatal neurons from PARK22/2 mice. Representative experiments with neurons or astrocytes
from striatum or cortex: the traces represent the evolution of the respiration rate (in pmol O2/minute) in Seahorse plates seeded with cells from
PARK2
2/2 (black circles) and wild type (white circles) mice. Sequential additions are: oligomycin (OM) (0.25 mg/ml for neurons and 0.5 mg/ml for
astrocytes), fccp (FP) (3 mM for cortical neurons and 1 mM for other cells), and rotenone+antimycine (RA) (50 nM rotenone+150 mg/ml antimycin A).
Bars below the traces show the means and SD of basal respiration, maximal respiration and spare respiratory capacity (SRC=maximal – basal
respiration) of 3 independent tests, each performed in 6 to 12 independent wells. * p,0.05 using Mann and Whitney test.
doi:10.1371/journal.pone.0099898.g003
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conditions and tissues examined, excluding excessive accumulation
of partially depolarized mitochondria in the absence of Parkin.
In both PARK22/2 and wild type brain ageing had a clear
impact on the Dym response to increasing doses of the uncoupler
cccp with a significant drop of the mean Dym under 8 mM cccp
treatment from 9 to 24 months of age in the striatum and
midbrain (p = 0.022 and 0.035 in midbrain and p= 0.001 and ,
0.001 in striatum of PARK22/2 and wild type mice respectively
using Mann and Whitney test) (Figure 4). The mean Dym under
the lower dose of 4 mM cccp was only significantly lower with age
in striatum (p= 0.014 and p=0.020 in striatum of PARK22/2 and
wild type mice respectively and p= 0.181 and 0.138 in midbrain).
The drop of Dym between condition C (highest value under
oligomycin) and condition F or G (uncoupled by either 4 or 8 mM
cccp) was then calculated for each mouse. In striatum and under
8 mM cccp only, that drop was significantly higher in PARK22/2
than in wild type mice (p= 0.041 with Mann and Whitney test).
In liver, despite a similar trend, the changes with age in the
mean response of Dym to uncoupling did not reach significance in
wild type or PARK22/2 mice.
In conclusion the absence of Parkin did not significantly alter
the mean Dym in midbrain, striatum and liver of PARK22/2 mice
Figure 4. The inner mitochondrial membrane potential is normal in midbrain and striatum of PARK22/2 mice. Dark circles = PARK22/2,
white circles =wild type; DYm= inner mitochondrial membrane potential expressed as mV after transformation of the fluorescent rhodamine 123
signal using the Nernst equation, as explained in the methods section; A =DYm in the presence of glutamate+malate; B =A+1 mM ADP; C = B+1 mM
oligomycin; D=C+1 mM cccp; E = C+2 mM cccp; F = C+4 mM cccp;G=C+8 mM cccp. The data were obtained in parallel to the analysis of respiration;
two animals, one per genotype, were analyzed the same day; the data obtained from seven 9-month-old mice and six 24-month-old ones of each
genotype, they are expressed as mean and SD.
doi:10.1371/journal.pone.0099898.g004
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but it was associated in striatum with a greater impact of ageing on
the Dym response to uncoupling.
The respiratory defect in PARK22/2 mice was not due to
defective complex I activity, altered mitochondrial
content or overt oxidative stress
Complex I activity has previously been reported to be lowered
in cells from PD patients with PARK2 mutations [25,29,30] and in
a Parkin-depleted zebrafish model [57]. Such a defect may
underlie the reduction in striatal tissue respiration and the
increased sensitivity of Dym to uncoupling in PARK22/2 mice.
To address this possibility, we used spectrophotometric methods
recently standardized for the diagnosis of human mitochondrial
diseases [47] to measure the respiratory chain activities in striatal
post-nuclear supernatants and crude mitochondrial pellets of
cortex and midbrain from one-year-old PARK22/2 and wild type
mice. All the respiratory chain activities examined were similar in
PARK2
2/2 and wild type mice (Table 1).
Citrate synthase, a citric acid cycle activity often used to evaluate
mitochondrial content [58], was also normal in PARK22/2. In
addition, cell mitochondrial DNA contents were similar in the
striatum of PARK22/2 and wild type mice, confirming that Parkin
deficiency does not have an impact on mitochondrial content
(16866119 copies/cell in PARK22/2 mice versus 1791694 in wild
type mice).
Post-translational modifications regulating the activity of
mitochondrial proteins involved in the import, catabolism or
oxidative phosphorylation of respiratory substrates could also
underlie the respiration defect observed in PARK22/2 mice.
Previous studies have reported alterations in proteins involved in
the defense against oxidative stress in these mice [35,36]. We
therefore searched for evidence of oxidative stress in midbrain and
striatum of PARK22/2mice. Ageing however being known to have
significant influence on oxidative stress, we analyzed the combined
influence of age and genotype on the parameters of oxidative stress
using multiple comparison by the Holm-Sidak test. Proteasome
activity significantly increased with age in striatum (p,0.001) but
not midbrain, without influence of the genotype (Table 2).
Similarly the midbrain mitochondrial glutathione content in-
creased with age (p,0.001 when comparing 12-month-old to 24
month-old mice) without influence of the genotype). In contrast,
significant interaction between age and genotype was observed for
the striatal mitochondrial glutathione content (p = 0.015). Ageing
led to a significant increase in striatal mitochondrial glutathione in
wild type mice (p,0.001 when comparing 12-month-old to 24
month-old wild type mice) but had no effect in PARK22/2 mice.
At 12 months of age the striatal mitochondrial glutathione levels
were significantly higher in PARK22/2 mice than in wild type
mice (p,0.011 when comparing 12-month-old wild type to 12-
month-old PARK22/2 mice with Mann and Whitney test).
Cytosolic glutathione levels did not change with age in midbrain.
In striatum cytosolic glutathione levels significantly decreased with
age (p,0.001 when comparing 12-month-old to 24 month-old
mice without influence of the genotype, Figure 5); interaction
between age and genotype just failed to reach significance
(p = 0.056).
In parallel nitrotyrosine (NT) and 4-hydroxynonenal (HNE),
two different protein oxidative adducts, were searched for in crude
mitochondrial pellets using western blot analysis. At 12 months of
age there was a significant increase in both adducts in the striatum
of PARK22/2 compared to wild type mice (p,0.001 and p= 0.016
for NT and HNE respectively with Mann and Whitney) (Figure 6).
At 24 months of age, PARK22/2 striatum showed increase in NT
only (p = 0.028 compared with wild type mice) whereas wild-type
mice showed an increase of HNE in midbrain (p = 0.003).
The steady-state of the mitochondrial superoxide dismutase 2
(SOD2), normally increased in the presence of mitochondrial
oxidative stress [59], was normal at 12 months of age and slightly
increased at 24 months of age in PARK22/2 mice compared to
wild type mice (p = 0.016 using Mann and Whitney test) (Figure 7).
Altogether, our results show an increase in oxidative stress in the
striatum mitochondria of PARK22/2 mice (increased glutathione
levels, increased oxidative adducts and, with age, increased SOD2
expression). That increase is however moderate (normal SOD2
expression at 12 months of age, normal proteasome activity).
Discussion
Recent work, based on the analysis of cell models overproduc-
ing Parkin and subjected to pharmacological treatments leading to
immediate and global depolarization of the mitochondrial
network, attributed to Parkin a central role in the clearance of
dysfunctional mitochondria [12]. These studies predict that loss of
function of the PINK1/Parkin pathway should lead to progressive
mitochondrial impairment, possibly representing a primary
Table 1. Activities of mitochondrial respiratory chain complexes in 12-month-old PARK22/2 and wild type mice.
Striatum Midbrain Cortex
PARK22/2 Wild type PARK22/2 Wild type PARK22/2 Wild type
Complex I 91626 93620 133631 138638 121627 111620
Complex II 76624 86621 248628 231664 190645 183638
Combined II+III 118642 97630 304681 326686 232682 283673
Complex III 78647 60619 3726121 376671 6966411 5836154
Complex IV 398678 386684 15856598 18756794 9596221 11126267
Complex V NA NA 1946139 171659 170694 185687
Citrate synthase 455633 458645 1946146 1716162 170696 185693
Striatum=post-nuclear supernatants from striatum, Midbrain = crude mitochondrial pellet from ventral midbrain, Cortex = crude mitochondrial pellet from occipital
cortex; complex I = rotenone sensitive NADH ubiquinone oxidoreductase, complex II = succinate ubiquinone oxidoreductase, combined II+III = succinate cytochrome c
oxidoreductase, complex III = antimycin sensitive ubiquinol cytochrome c oxidoreductase, complex IV = cytochrome c oxidase, complex V = F1F0 ATPsynthase; complex
V assay requires mitochondrial preparation and was therefore not performed on striatal post-nuclear supernatants; data are expressed as nanomoles/minute and mg
proteins and as means 6 SD; each series of values represents 7 independent samples from each genotype.
doi:10.1371/journal.pone.0099898.t001
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mechanism of neurodegeneration in autosomal recessive PD.
However, whether Parkin-dependent mitochondrial quality con-
trol plays indeed a role in vivo under physiological conditions and
during aging, remains debated.
We addressed this issue by revisiting mitochondrial functions in
PARK2
2/2 mice using recently developed, robust and sensitive
technologies. The simultaneous analysis of minimal amounts of
post-nuclear supernatants from different tissues with high resolu-
tion respirometry revealed a reliable respiratory defect specifically
in the striatum of PARK22/2 mice, which was not exacerbated by
ageing. The presence of this defect was confirmed in primary
embryonic striatal neurons and was not found in cortical neurons
from PARK22/2 mice using the Seahorse technology, supporting
its region-specificity and early appearance in life.
Contrary to previous observations in cell and zebrafish models
[25,29,57], the constitutive deletion of PARK2 in mice did not
result in significant changes in mitochondrial membrane potential,
overt oxidative stress markers or defective activity of mitochondrial
complex I or other respiratory chain complexes despite the
presence of significant respiratory defect. With ageing however the
mitochondrial potential in the striatum showed increased sensitiv-
ity to uncoupling, with a greater impact in PARK22/2 than in wild
Figure 5. Increase of the mitochondrial glutathione content in striatum of 12-month-old PARK22/2mice. Total glutathione (GSH+GS-SG)
levels were determined in cytosols and isolated mitochondria from ventral midbrain and striatum of 12- and 24-month-old PARK22/2 (black bars) and
wild-type mice (white bars), data are expressed as mean and SD of five independent measurements for each age and each genotype. * = p,0.05
using multiple comparison with Holm-Sidak test. Significant differences with age, without influence of the genotype, were observed for midbrain
mitochondrial and striatal cytosolic glutathione content. Significant interaction between age and genotype was present for striatal mitochondrial
glutathione content, which significantly increased with age only in wild type mice and was at 12 months of age significantly higher in PARK22/2 than
in wild type mice.
doi:10.1371/journal.pone.0099898.g005
Table 2. Proteasome activities were similar in PARK22/2 and wild type mice.
Tissue Midbrain Striatum
Age 12 months 24 months 12 months 24 months
PARK22/2 116689 84612 4368 776110
wild type 94637 80613 4364 6367
Chymotrypsin-like activity of the proteasome. Results are expressed as nmoles of substrate cleaved/minute and milligram of protein and as mean6standard deviation
of n = 5 measurements.
doi:10.1371/journal.pone.0099898.t002
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type mice, indicating less efficient compensation for an induced
proton leak. As this defect cannot be ascribed to an age-dependent
decline of respiratory capacity, it may be secondary to an age-
dependent alteration of the inner membrane composition or defect
in OXPHOS substrate transport or oxidation, all of which could
add a burden to the preexisting respiration defect in PARK22/2
mice.
The relatively mild modifications of mitochondrial function in
PARK2
2/2 mice suggest that Parkin does not play a predominant
role in base-line mitochondrial quality control in vivo. Its
constitutive depletion may be compensated for by parallel,
redundant or alternative mitochondrial quality control mecha-
nisms, already proposed to intervene following PINK1 depletion
[60]. This possibility is supported by the recent observation in the
heart of PARK22/2 mice showing absence of a functional defect of
mitochondria in the myocardium under basal conditions but
defective clearing of damaged mitochondria following myocardiac
infarction [61] and accumulation of mitochondria with abnormal
ultrastructure in myocytes during aging [62]. Therefore, as in
cardiac tissue, the mitochondrial quality control function of the
PINK1/Parkin pathway may become essential in the central
nervous system under stress conditions, for example following
accumulation of oxidative stress during ageing [63]. Consistent
with this possibility, mitochondrial stress caused by the conditional
expression of mitochondrial unfolded ornithine transcarbamylase
has been recently shown to lead to dopaminergic neurodegener-
ation and a parkinsonian phenotype in PINK12/2 mice [64].
Contrary to humans, the short life-time of rodents may not
allow full unmasking of a phenotype following disruption of the
PINK1/Parkin pathway, explaining the moderate mitochondrial
defect and lack of overt neurodegeneration in PARK22/2 mice.
Signs of oxidative damage were mild in aged PARK22/2 mice.
Compensatory mechanisms such as the increase in glutathione
levels, specifically in the mitochondrial fraction, may enhance the
cellular antioxidant capacity and counteract oxidative stress in
these mice. The relative content of reduced and oxidized
glutathione should be determined in this fraction to properly
evaluate the efficiency of this mechanism. Of note, we previously
reported a selective increase in reduced glutathione content in
total extracts from striatum and primary mesencephalic neurons of
PARK22/2 mice [39]. The increase of SOD2, often used as a
marker of oxidative stress, is also a protective mechanism
efficiently neutralizing superoxide anions.
In conclusion, our work revealed an early respiration defect in
PARK22/2 mice that may reflect a disease-relevant preclinical
modification in autosomal recessive PD. Future studies are
required to identify the molecular mechanisms underlying this
modification and determine their relation to the mitochondrial
quality control activity of the PINK1/Parkin pathway. To fully
appreciate the role of PINK1/Parkin-dependent mitochondrial
quality control in the physiopathology of autosomal recessive PD,
it will also be essential to determine whether stress conditions
Figure 6. Presence of oxidative adducts in striatal crude
mitochondrial pellets from PARK22/2 mice. Western blot analysis
of proteins from crude mitochondrial pellets from striatum (A) and
midbrain (B) of PARK22/2 and wild-type mice, at 12 and 24 months of
age; loading control was the outer membrane protein Voltage-
Dependent Anion Channel (VDAC); (C) densitometric analysis of
oxidative adducts was performed in the length of the membrane
shown in A and B, that signal was then normalized to VDAC signal and
quantification was expressed as means and SD and as % of the mean of
wild-type samples on the membrane shown in A and B; * = p,0.05
using Mann and Whitney test.
doi:10.1371/journal.pone.0099898.g006
Figure 7. Increased mitochondrial Mn superoxide dismutase
(SOD2) in the striatum of PARK22/2 mice. Western blot analysis of
proteins from crude mitochondrial pellets from striatum (A) and
midbrain (B) of PARK22/2 and wild-type mice, at 12 and 24 months
of age; loading control was the outer membrane protein Voltage-
Dependent Anion Channel (VDAC); (C) densitometric analysis of the
SOD2 signal shown in A and B was normalized to VDAC signal and
quantification was expressed as means and SD and as % of the mean of
wild-type samples on the membrane shown in A and B; * = p,0.05
using Mann and Whitney test; { and `: samples from 12-month-old
PARK2
2/2 and wild type mice respectively showing that the SOD2
steady-state level does not significantly change with age.
doi:10.1371/journal.pone.0099898.g007
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exacerbate mitochondrial dysfunction and unmask a neurodegen-
erative phenotype in the brains of PARK22/2 mice.
Supporting Information
Figure S1 Scheme of the different brain fractionation
methods used to assess mitochondrial functions.
(TIF)
Figure S2 Respiratory control ratios (RCR) in 24-
month-old mice. Respiratory control ratios were calculated as
state 3/state 4 respiration rate on glutamate+malate as substrates;
results are shown as mean and SD; numbers between brackets
indicate the number of independent measurements in individual
animals of each genotype (A) crude mitochondrial pellets from
cortex (n = 8), crude mitochondrial pellets from striatum (n= 6)
and purified mitochondrial pelllets from whole brain (n = 2); (B)
post-nuclear supernatants from striatum (n= 7), midbrain (n = 8)
and liver (n = 8).
(TIF)
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